The center for biologics evaluation and research (cber) purchase order for dbpap/ AMB a 1-specific aptamers.

Ended Purchase Order Awarded Last action

Contract number
75F40124P00523
Awardee
Awarding agency
Obligated
$100,000

Award facts

Opportunity
Contract value 100% obligated
$100,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
3 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Jacobus, PA 17407, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $100,000

About this award

The Food and Drug Administration awarded a purchase order to Aptagen LLC for $100,000.00 on September 27, 2024, for development of Amb a 1-specific aptamers for use in enzyme-linked immunosorbent assay and immunoenzymometric assay protocols to measure biological potency of commercial ragweed pollen extracts. Work is performed in Jacobus, Pennsylvania. The order carries a total small business set-aside and concludes September 26, 2025. The originating solicitation, posted September 19, 2024 with a September 27, 2024 due date, sought a three-phase technical approach encompassing preliminary screening, selection, and screening/characterization of capture and biotin-labeled detection aptamers.

Quick answers

Who was awarded contract 75F40124P00523?

75F40124P00523 was awarded to Aptagen LLC by Food and Drug Administration (Department of Health and Human Services) on September 27, 2024.

How much is contract 75F40124P00523 worth?

The government has obligated $100,000 on 75F40124P00523.

Was contract 75F40124P00523 competed?

The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award